U.S. Capital Wealth Advisors, LLC Crispr Therapeutics Ag Transaction History

U.S. Capital Wealth Advisors, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 03, 2023	SELL	$39.19 - $65.67 $3,527 - $5,910	-90 Reduced 0.41%	22,066 $896,000
Q3 2022 Nov 01, 2022	SELL	$61.1 - $83.78 $25,356 - $34,768	-415 Reduced 1.84%	22,156 $1.45 Million
Q2 2022 Aug 12, 2022	SELL	$43.23 - $73.83 $12,968 - $22,149	-300 Reduced 1.31%	22,571 $1.37 Million
Q1 2022 May 12, 2022	BUY	$53.19 - $79.24 $393,978 - $586,930	7,407 Added 47.9%	22,871 $1.44 Million
Q4 2021 Jan 21, 2022	BUY	$70.09 - $111.29 $384,023 - $609,757	5,479 Added 54.87%	15,464 $1.17 Million
Q3 2021 Nov 01, 2021	BUY	$110.2 - $156.64 $1.1 Million - $1.56 Million	9,985 New	9,985 $1.12 Million

491

58M

1.1M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.74B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of U.S. Capital Wealth Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on U.S. Capital Wealth Advisors, LLC with notifications on news.